PHYTOMENADIONE

Phytomenadione received initial approval from the United States Food and Drug Administration (FDA) on 19 June 1941.

Phytomenadione regulates blood clotting, reverses anticoagulant effects, prevents bleeding issues in newborns, supports bone health, and manages clotting function in conditions like malabsorption or liver disease. This medication also helps in hemostasis in gastrointestinal bleeding and treats coumarin-induced skin necrosis.

Phytomenadione can be administered through multiple routes, including oral ingestion through tablets or liquid, intravenous injection, and intramuscular injection into a muscle. The specific route chosen depends on the patient's condition, urgency of treatment, and healthcare provider's recommendation.

Side effects of Phytomenadione are generally rare and mild, with common ones including minor injection site discomfort or mild gastrointestinal symptoms. Serious side effects are uncommon but could involve severe allergic reactions with symptoms like rash, swelling, or difficulty breathing. In rare cases, unusual bleeding or bruising might occur.

Allergic reactions such as rash, itching, swelling, or difficulty breathing can occur with using Phytomenadione. Unusual bleeding, bruising, or bleeding that does not stop can be also seen. This medication could also affect clotting factors. Although rare, sensitivity to sunlight might occur.

If you experience signs of an allergic reaction, such as rash, itching, swelling, or difficulty breathing, seek medical help immediately. If you notice unusual bleeding, bruising, or bleeding that does not stop, inform your healthcare provider. Inform surgeons or dentists about it before undergoing procedures. Do not stop using Phytomenadione abruptly without consulting your healthcare provider. If taking anticoagulant medications like warfarin, follow your healthcare provider's recommendations closely. Use sun protection measures.

Inform your healthcare provider of allergies, medical history, and current medications before beginning Phytomenadione. Discuss potential allergic reactions, unusual bleeding, or bruising. Pregnant or breastfeeding individuals require medical advice before use. Exercise caution if you have liver or lung conditions, and discuss any interactions with alcohol. Dosage, particularly for children and older adults, must be followed exactly as directed by your healthcare professional. Before undergoing surgery or dental procedures, inform the relevant professionals of your Phytomenadione use. Regular monitoring and ongoing communication with your healthcare provider are essential for patients taking anticoagulants. Do not discontinue without professional guidance. While sunlight exposure does not directly affect Phytomenadione, sun protection remains advisable. Your healthcare provider can offer personalised advice to ensure safe and effective use of this medication.

Neon Healthcare Limited, Electronic Medicines Compendium (EMC), [Revised on 16 Feb 2022] [Accessed on 19th August 2023], https://www.medicines.org.uk/emc/product/9755/smpc#gref Valdepharm, US Food, and Drug Administration, [Revised on May 2018] [Accessed on 19th August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012223s042lbl.pdf P. Hanlon, M. Byers, J.P.H. Wilding and H.M. Macdonald, Environmental and nutritional factors in disease, Davidson’s Principles, and Practice of Medicine, 22nd Edition, 2014, 97-132.